NEW YORK (GenomeWeb News) – Gamma-Dynacare Medical Laboratories announced today the completion of its acquisition of a controlling interest in Impact Genetics.
Terms of the purchase were not disclosed.
Impact Genetics is a laboratory based in Toronto that provides high-complexity, disease-specific genetic testing. Its test menu includes retinoblastoma RB, hereditary hemorrhagic telangiectasia, Von Hippel-Lindau Syndrome VHL, and gene copy analysis and plans to launch new tests targeting uveal melanoma and inherited leukemia soon. The company serves customers throughout North America, Asia, and Europe.
During the next few months, Impact Genetics' operations will move to Gamma-Dynacare's center of excellence for pathology, immunopathology, genetics, and pharmacogenomics testing in Bowmanville, Ontario, near Toronto.
Franny Jewett, CEO of Impact, along with Medical Director Brenda Gallie and the entire team at the firm will remain in their respective roles with the company, Gamma-Dynacare said.
"This investment brings to Gamma-Dynacare expanded capabilities in molecular medicine, oncology, and genetic testing for rare diseases that will enhance our continued growth in the field of personalized medicine," Gamma-Dynacare President and CEO Naseem Somani said in a statement.
The company provides laboratory services and solution and operates nine laboratories in Ontario, Quebec, Manitoba, and Alberta.